These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
3. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469 [TBL] [Abstract][Full Text] [Related]
4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
5. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751 [TBL] [Abstract][Full Text] [Related]
8. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
10. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590 [TBL] [Abstract][Full Text] [Related]
11. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427 [TBL] [Abstract][Full Text] [Related]
12. Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259 [TBL] [Abstract][Full Text] [Related]
14. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234 [TBL] [Abstract][Full Text] [Related]
15. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study. Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723 [TBL] [Abstract][Full Text] [Related]
16. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. Komori T Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304 [TBL] [Abstract][Full Text] [Related]
17. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499 [TBL] [Abstract][Full Text] [Related]
18. Clinical implications of molecular analysis in diffuse glioma stratification. Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651 [TBL] [Abstract][Full Text] [Related]
20. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas. Terzi NK; Yilmaz I; Oz AB Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]